Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Female cancer incidence before and after diagnosis of primary Sjögren's disease : A retrospective cohort study

Sjöström, Bitte LU ; Bredberg, Anders LU ; Olsson, Peter LU orcid ; Ullén, Susann LU and Henriksson, Gunnel LU (2026) In Journal of Translational Autoimmunity 12.
Abstract

In primary Sjögren's disease (pSjD), there is a well-documented increased risk of hematological malignancies, particularly lymphomas, whereas studies examining the incidence of solid tumors have often yielded conflicting results. Data concerning the incidence of breast and gynecological cancers are similarly inconsistent. The aim of this study was to further investigate the incidence of these so-called female cancers by assessing not only their occurrence following the diagnosis of pSjD but also prior to it. By linking the Malmö Sjögren's disease register with the Swedish National Cancer Register, 25 cases of female cancers were identified among patients with pSjD (mean follow-up time: 45.8 years), compared to 50.70 expected cases (SIR,... (More)

In primary Sjögren's disease (pSjD), there is a well-documented increased risk of hematological malignancies, particularly lymphomas, whereas studies examining the incidence of solid tumors have often yielded conflicting results. Data concerning the incidence of breast and gynecological cancers are similarly inconsistent. The aim of this study was to further investigate the incidence of these so-called female cancers by assessing not only their occurrence following the diagnosis of pSjD but also prior to it. By linking the Malmö Sjögren's disease register with the Swedish National Cancer Register, 25 cases of female cancers were identified among patients with pSjD (mean follow-up time: 45.8 years), compared to 50.70 expected cases (SIR, 0.49; 95 % CI, 0.30–0.69; P < 0.001). The incidence of female cancers was significantly reduced both prior to ( P < 0.001) and following ( P < 0.001) the diagnosis of pSjD. The decrease was most evident for breast cancer (SIR, 0.46; 95 % CI, 0.24–0.69; P < 0.001). A reduction was also noted for ovarian cancer (SIR, 0.21; 95 % CI, 0.00–0.62; P < 0.001); however, the reliability of this estimate is limited by the small number of observed cases. Our findings suggest a reduced risk of female cancers, primarily driven by a decrease in breast cancer incidence, not only following but also preceding the diagnosis of pSjD. These results, combined with the observation that autoantibodies characteristic of pSjD often emerge several years before clinical onset, raise the question of whether an autoimmune component may confer a protective effect against breast cancer in pSjD.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Autoantibodies, Breast cancer, Female cancer, Gynecological cancer, Sjögren's disease, Sjögren's syndrome
in
Journal of Translational Autoimmunity
volume
12
article number
100352
publisher
Elsevier
external identifiers
  • scopus:105029126657
ISSN
2589-9090
DOI
10.1016/j.jtauto.2026.100352
language
English
LU publication?
yes
id
305fe193-a48c-42e5-94b4-b5e919633e5f
date added to LUP
2026-02-18 08:45:12
date last changed
2026-02-18 08:46:06
@article{305fe193-a48c-42e5-94b4-b5e919633e5f,
  abstract     = {{<p>In primary Sjögren's disease (pSjD), there is a well-documented increased risk of hematological malignancies, particularly lymphomas, whereas studies examining the incidence of solid tumors have often yielded conflicting results. Data concerning the incidence of breast and gynecological cancers are similarly inconsistent. The aim of this study was to further investigate the incidence of these so-called female cancers by assessing not only their occurrence following the diagnosis of pSjD but also prior to it. By linking the Malmö Sjögren's disease register with the Swedish National Cancer Register, 25 cases of female cancers were identified among patients with pSjD (mean follow-up time: 45.8 years), compared to 50.70 expected cases (SIR, 0.49; 95 % CI, 0.30–0.69; P &lt; 0.001). The incidence of female cancers was significantly reduced both prior to ( P &lt; 0.001) and following ( P &lt; 0.001) the diagnosis of pSjD. The decrease was most evident for breast cancer (SIR, 0.46; 95 % CI, 0.24–0.69; P &lt; 0.001). A reduction was also noted for ovarian cancer (SIR, 0.21; 95 % CI, 0.00–0.62; P &lt; 0.001); however, the reliability of this estimate is limited by the small number of observed cases. Our findings suggest a reduced risk of female cancers, primarily driven by a decrease in breast cancer incidence, not only following but also preceding the diagnosis of pSjD. These results, combined with the observation that autoantibodies characteristic of pSjD often emerge several years before clinical onset, raise the question of whether an autoimmune component may confer a protective effect against breast cancer in pSjD.</p>}},
  author       = {{Sjöström, Bitte and Bredberg, Anders and Olsson, Peter and Ullén, Susann and Henriksson, Gunnel}},
  issn         = {{2589-9090}},
  keywords     = {{Autoantibodies; Breast cancer; Female cancer; Gynecological cancer; Sjögren's disease; Sjögren's syndrome}},
  language     = {{eng}},
  publisher    = {{Elsevier}},
  series       = {{Journal of Translational Autoimmunity}},
  title        = {{Female cancer incidence before and after diagnosis of primary Sjögren's disease : A retrospective cohort study}},
  url          = {{http://dx.doi.org/10.1016/j.jtauto.2026.100352}},
  doi          = {{10.1016/j.jtauto.2026.100352}},
  volume       = {{12}},
  year         = {{2026}},
}